pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1231 |
Genomic Coordinates | chr1: 201808611 - 201808702 |
Synonyms | MIRN1231, hsa-mir-1231, MIR1231 |
Description | Homo sapiens miR-1231 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1231 | |||||||||||||||
Sequence | 5| GUGUCUGGGCGGACAGCUGC |24 | |||||||||||||||
Evidence | Experimental | |||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||
SNPs in miRNA |
|
|||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | WNT10A | ||||||||||||||||||||
Synonyms | OODD, SSPS, STHAG4 | ||||||||||||||||||||
Description | Wnt family member 10A | ||||||||||||||||||||
Transcript | NM_025216 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on WNT10A | |||||||||||||||||||||
3'UTR of WNT10A (miRNA target sites are highlighted) |
>WNT10A|NM_025216|3'UTR 1 GCGGCCCGGGGTCCCCTGGGCCCTGATCGAGGTCCCCTCCTGGAGCCTGGCCCTCTGAGGCTTACGGTCTTGGCAAGGCA 81 GCATCGCCTTGGCTCTTGGGAAGAGGAGATTGGACCACATGATCTTATAGGAACCCCTCAGCTCTGAGGTCTGTGATCGC 161 CGGACAGTCCAGGCCTGTCTGAACCCCACCACTCACTTCTGTGGGCTCTAGGACTGACTGGGTTCTTCCTCCCTCCCCGA 241 AGCCCAGACAGTTCAGTTGGGCTGGGGGTTGCTCCACACCCTAAAACAAGCCTCAGCCAGGCAACCCGTCAGTCTGTCTC 321 CATCCTTTCACCCCTTCCCTGGAGATGGGAGGTGGGGAATGAATGGAAGCTGACGGGCAGAGAGAGGAGGATTAAAAAAA 401 AGAAATAGACATAACTGAGCTGAAGTAATTCCATAAAGGGCCCAGACAGCCTCCTCCACCATTCCCTTCATCATTCATTT 481 AACAAATATTTATTTTGCACTCTCTTTGCGGCACTCTGGGGGCGGTGGGGTGCGTGGGGGTGGCAATGCAAGGCACTGAG 561 GCCACAGATGTGAGTAAGCGAGACACAACACTTGTCCTCTTGGAGGTTACATTCTTGCTGGGGGGAGGCATGGGCAATAA 641 ACAAGTAAATATACAAAC Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | hESCs (WA-09) | ||||||
Disease | 80326.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
CLIP-seq Support 1 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000258411.3 | 3UTR | GCCCAGACAGUUCAGUUGGGCUGGGG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
37 hsa-miR-1231 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT075228 | PHF13 | PHD finger protein 13 | 2 | 6 | ||||||||
MIRT266936 | HDGF | heparin binding growth factor | 2 | 6 | ||||||||
MIRT441394 | SOX5 | SRY-box 5 | 2 | 2 | ||||||||
MIRT446329 | ATP5C1 | ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 | 2 | 2 | ||||||||
MIRT446438 | THYN1 | thymocyte nuclear protein 1 | 2 | 2 | ||||||||
MIRT482781 | STIM1 | stromal interaction molecule 1 | 2 | 2 | ||||||||
MIRT497714 | CYP1A1 | cytochrome P450 family 1 subfamily A member 1 | 2 | 2 | ||||||||
MIRT500907 | STARD13 | StAR related lipid transfer domain containing 13 | 2 | 2 | ||||||||
MIRT503251 | KIF18B | kinesin family member 18B | 2 | 2 | ||||||||
MIRT504750 | TEP1 | telomerase associated protein 1 | 2 | 4 | ||||||||
MIRT512158 | CD164 | CD164 molecule | 2 | 6 | ||||||||
MIRT518043 | LSM3 | LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated | 2 | 4 | ||||||||
MIRT526038 | GMDS | GDP-mannose 4,6-dehydratase | 2 | 2 | ||||||||
MIRT529828 | ARGFX | arginine-fifty homeobox | 2 | 2 | ||||||||
MIRT531808 | POLD3 | DNA polymerase delta 3, accessory subunit | 2 | 2 | ||||||||
MIRT533139 | WNT10A | Wnt family member 10A | 2 | 2 | ||||||||
MIRT538612 | CCT5 | chaperonin containing TCP1 subunit 5 | 2 | 4 | ||||||||
MIRT555617 | PHLPP2 | PH domain and leucine rich repeat protein phosphatase 2 | 2 | 2 | ||||||||
MIRT561705 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | 2 | 2 | ||||||||
MIRT562301 | GINM1 | glycoprotein integral membrane 1 | 2 | 2 | ||||||||
MIRT566732 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT569369 | IMPG1 | interphotoreceptor matrix proteoglycan 1 | 2 | 2 | ||||||||
MIRT572314 | HSPB6 | heat shock protein family B (small) member 6 | 2 | 2 | ||||||||
MIRT574602 | LZIC | leucine zipper and CTNNBIP1 domain containing | 2 | 2 | ||||||||
MIRT612023 | FOXF2 | forkhead box F2 | 2 | 2 | ||||||||
MIRT616950 | MAPKAPK2 | mitogen-activated protein kinase-activated protein kinase 2 | 2 | 2 | ||||||||
MIRT624175 | DERL2 | derlin 2 | 2 | 2 | ||||||||
MIRT647634 | FAIM2 | Fas apoptotic inhibitory molecule 2 | 2 | 2 | ||||||||
MIRT659393 | CORO2A | coronin 2A | 2 | 2 | ||||||||
MIRT659955 | CXCL10 | C-X-C motif chemokine ligand 10 | 2 | 2 | ||||||||
MIRT684001 | FOLR1 | folate receptor 1 | 2 | 2 | ||||||||
MIRT688143 | GABPB1 | GA binding protein transcription factor beta subunit 1 | 2 | 2 | ||||||||
MIRT688609 | CYBRD1 | cytochrome b reductase 1 | 2 | 2 | ||||||||
MIRT693583 | SLC39A1 | solute carrier family 39 member 1 | 2 | 2 | ||||||||
MIRT699922 | RUFY2 | RUN and FYVE domain containing 2 | 2 | 2 | ||||||||
MIRT712961 | PET117 | PET117 homolog | 2 | 2 | ||||||||
MIRT723950 | TMEM184A | transmembrane protein 184A | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|